Potential downsides Itll be no surprise to hear, though, that nothing comes without risk
Contrave is generally indicated for adults with obesity or those who are overweight and have at least one weight-related comorbidity, such as high blood pressure, type 2 diabetes, or high cholesterol
This was considered a breakthrough, as it proved that hormonal modulation could produce sustained weight reduction far exceeding previous pharmacological options
Similarly, liraglutide for diabetes (Victoza) starts at 0.6 mg daily, escalating to 1.2 mg and potentially 1.8 mg if needed, while liraglutide for weight management (Saxenda) follows a schedule from 0.6 mg to 3.0 mg daily (via 1.2 mg, 1.8 mg, and 2.4 mg steps)
NICE recommends it (Technology Appraisal TA875) for adults with a BMI of 35 kg/m or above with at least one weight-related comorbidity, or a BMI of 3034.9 kg/m in certain higher-risk groups, when used within a specialist Tier 3 or Tier 4 weight management service alongside a reduced-calorie diet and increased physical activity
(Comparative